Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactobacillus paracasei ET-66
- Development stage
- Unknown
- Lead developer
- Bioflag Biotech
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral, Buccal
01
Overview
Lactobacillus paracasei ET-66 is a probiotic bacterial strain isolated from healthy human breast milk. It is primarily developed for oral health applications, demonstrating the ability to inhibit the growth of oral pathogens such as Aggregatibacter actinomycetemcomitans and Streptococcus mutans. Clinical evidence suggests that ET-66, administered in lozenge or tablet form (either as viable cells or heat-killed paraprobiotics), enhances oral mucosal immunity by stimulating the production of salivary secretory IgA and modulating the expression of anti-inflammatory cytokines, including IL-10 and TGF-beta. The strain is also associated with reduced dental plaque formation and improved oral microbiota balance.
- Other names
- Lacticaseibacillus paracasei ET-66
02
Targets
IL10 (Interleukin-10)IgA (Immunoglobulin A)TGFB (GARP–latent transforming growth factor beta 1 complex)
Beyond the preview
Go deeper on lactobacillus paracasei ET-66.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactobacillus paracasei ET-66.